Skip to main content

Featured

Territorial Disputes Dominate Geneva Peace Talks

US President Donald Trump's son-in-law Jared Kushner, US Special Envoy Steve Witkoff, US Secretary of State Marco Rubio, US Army Secretary Daniel Driscoll sit before closed-door talks with Head of the Office of the President of Ukraine Andriy Yermak  (not pictured) on ending Russia's war in Ukraine, at the US Mission in Geneva, Switzerland. Negotiators from Russia and Ukraine convened in Geneva for a new round of U.S.-mediated peace talks, with territorial disputes emerging as the central point of contention. The discussions, held over two days, come amid heightened pressure from U.S. President Donald Trump, who has urged Kyiv to “come to the table fast” in pursuit of a settlement.  Both sides remain deeply divided over land claims, which have become the primary obstacle to progress. The Kremlin has signaled that territorial issues will dominate the agenda, while Ukrainian President Volodymyr Zelenskyy has voiced concerns that Kyiv is facing disproportionate p...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment